Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma

THEODOROS P. VASSILAKOPOULOS, MARIE-CHRISTINE KYRTSONIS, ARGIROULA PAPADOGIANNIS, GIANPAOLO NADALI, MARIA K. ANGELOPOULOU, TATIANA TZENOU, MARIA N. DIMOPOULOU, MARINA P. SIAKANTARIS, FLORA N. KONTOPIDOU, CHRISTINA KALPADAKIS, STYLIANI I. KOKORIS, EVANGELIA M. DIMITRIADOU, PANAYIOTIS TSAFTARIDIS, GIOVANNI PIZZOLO and GERASSIMOS A. PANGALIS
Anticancer Research November 2005, 25 (6C) 4743-4746;
THEODOROS P. VASSILAKOPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIE-CHRISTINE KYRTSONIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARGIROULA PAPADOGIANNIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIANPAOLO NADALI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA K. ANGELOPOULOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TATIANA TZENOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA N. DIMOPOULOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARINA P. SIAKANTARIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FLORA N. KONTOPIDOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTINA KALPADAKIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STYLIANI I. KOKORIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVANGELIA M. DIMITRIADOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PANAYIOTIS TSAFTARIDIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIOVANNI PIZZOLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERASSIMOS A. PANGALIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pangalis@med.uoa.gr
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Sternberg (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL. Patients and Methods: Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-matched healthy individuals. Results: The levels of syndecan-1 were higher in HL patients than controls (100.2±35.9 ng/ml vs. 67.9±24.5 ng/ml, p<0.001). They marginally correlated with advanced age (p=0.06), male gender (p=0.07) and consequently high IPS (p=0.01), but did not correlate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70±9% vs. 50±11% (p=0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml. Conclusion: The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation.

  • Hodgkin's
  • lymphoma
  • syndecan-1
  • serum levels

Footnotes

  • Received June 24, 2005.
  • Accepted July 28, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (6C)
Anticancer Research
Vol. 25, Issue 6C
1 Nov 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma
THEODOROS P. VASSILAKOPOULOS, MARIE-CHRISTINE KYRTSONIS, ARGIROULA PAPADOGIANNIS, GIANPAOLO NADALI, MARIA K. ANGELOPOULOU, TATIANA TZENOU, MARIA N. DIMOPOULOU, MARINA P. SIAKANTARIS, FLORA N. KONTOPIDOU, CHRISTINA KALPADAKIS, STYLIANI I. KOKORIS, EVANGELIA M. DIMITRIADOU, PANAYIOTIS TSAFTARIDIS, GIOVANNI PIZZOLO, GERASSIMOS A. PANGALIS
Anticancer Research Nov 2005, 25 (6C) 4743-4746;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma
THEODOROS P. VASSILAKOPOULOS, MARIE-CHRISTINE KYRTSONIS, ARGIROULA PAPADOGIANNIS, GIANPAOLO NADALI, MARIA K. ANGELOPOULOU, TATIANA TZENOU, MARIA N. DIMOPOULOU, MARINA P. SIAKANTARIS, FLORA N. KONTOPIDOU, CHRISTINA KALPADAKIS, STYLIANI I. KOKORIS, EVANGELIA M. DIMITRIADOU, PANAYIOTIS TSAFTARIDIS, GIOVANNI PIZZOLO, GERASSIMOS A. PANGALIS
Anticancer Research Nov 2005, 25 (6C) 4743-4746;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Heparanase promotes Syndecan-1 expression to mediate fibrillar collagen and mammographic density in human breast tissue cultured ex vivo
  • Google Scholar

More in this TOC Section

  • Palliative Radiotherapy for Large Osteolytic Metastatic Tumors Involving the Iliac Bone: A Report of 16 Cases
  • Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma
  • The Long-term Outcomes of Borderline Resectable T3 in Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Triplet Chemotherapy
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire